Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants

Abstract

Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.

1 - 7 . (Canceled without prejudice)  
     
     
         8 . A method of preventing dermatitis in a human which comprises administering to a human a pharmaceutical composition consisting essentially of a therapeutically effective amount of optically pure (−) cetirizine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.  
     
     
         9 . The method of  claim 8 , wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor, a 5-lipoxygenase activating protein antagonist, a leukotriene receptor antagonist, or a mixtures thereof.  
     
     
         10 - 13 . (Canceled without prejudice)  
     
     
         14 . A method of preventing allergic rhinitis in a human which comprises administering to a human a pharmaceutical composition consisting essentially of a therapeutically effective amount of optically pure (−) cetirizine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.  
     
     
         15 . The method of  claim 14 , wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor, a 5-lipoxygenase activating protein antagonist, a leukotriene receptor antagonists, or a mixtures thereof.  
     
     
         16 - 19 . (Canceled without prejudice)  
     
     
         20 . A method of preventing inflammation in a human which comprises administering to a human a pharmaceutical composition consisting essentially of a therapeutically effective amount of optically pure (−) cetirizine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.  
     
     
         21 . The method of  claim 20 , wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor, a 5-lipoxygenase activating protein antagonist, a leukotriene receptor antagonist, or a mixture thereof.  
     
     
         22 - 25 . (Canceled without prejudice)  
     
     
         26 . A method of preventing a condition responsive to leukotriene inhibition which comprises administering to a human a pharmaceutical composition consisting essentially of a therapeutically effective amount of optically pure (−) cetirizine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof.  
     
     
         27 . The method of  claim 26 , wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor, a 5-lipoxygenase activating protein antagonist, a leukotriene receptor antagonist, or a mixture thereof.  
     
     
         28 - 31 . (Canceled without prejudice)  
     
     
         32 . The method of  claim 26  wherein the condition responsive to leukotriene inhibition comprises asthma or a symptom thereof.  
     
     
         33 . The method of  claim 26  wherein the condition responsive to leukotriene inhibition comprises an allergic condition.  
     
     
         34 . The method of  claim 26  wherein the condition responsive to leukotriene inhibition comprises inflammation.  
     
     
         35 - 44 . (Canceled without prejudice)  
     
     
         45 . A pharmaceutical composition which comprises: 
 (a) a therapeutically effective amount of optically pure (−) cetirizine, or a pharmaceutically acceptable salt thereof;    (b) a therapeutically effective amount of a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor, a 5-lipoxygenase activating protein antagonist, and a leukotriene receptor antagonist, and or a mixture thereof, and    (c) a pharmaceutically acceptable carrier or excipient.    
     
     
         46 . A pharmaceutical composition which comprises from about 0.1 mg to 50 mg of optically pure (−) cetirizine, or a pharmaceutically acceptable salt thereof, and from about 2 mg to about 100 mg of leukotriene receptor antagonist, or a pharmaceutically acceptable salt thereof.  
     
     
         47 . A pharmaceutical composition which comprises from about 0.1 mg to 50 mg of optically pure (−) cetirizine, or a pharmaceutically acceptable salt thereof, and from about 20 mg to about 2500 mg of 5-lipoxygenase inhibitor, or a pharmaceutically acceptable salt thereof.  
     
     
         48 . A pharmaceutical composition which comprises from about 0.1 mg to 50 mg of optically pure (−) cetirizine, or a pharmaceutically acceptable salt thereof, and from about 20 mg to about 2500 mg of 5-lipoxygenase activating protein antagonist, or a pharmaceutically acceptable salt thereof.  
     
     
         49 . The pharmaceutical composition of  claim 45  which further comprises a therapeutically effective amount of a decongestant, or a pharmaceutically acceptable salt thereof.  
     
     
         50 - 52 . (Canceled without prejudice)